China Pharma Holdings (CPHI) Research & Development (2013 - 2026)
China Pharma Holdings (CPHI) posted Research & Development of $83762.0 for Q1 2026, down 55.92% on a QoQ basis from $190041.0 in Q4 2025, and up 183.1% year-over-year from $29587.0 in Q1 2025.
China Pharma Holdings (CPHI) Research & Development (2013 - 2026) Analysis & Trends
China Pharma Holdings' Research & Development history runs 14 years deep, the most recent figure standing at $83762.0 for Q1 2026.
- Quarterly Research & Development rose 183.1% year-over-year to $83762.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335076.0 (up 18.79% YoY) and the FY2025 annual result came in at $280901.0, down 1.07% from the prior year.
- Research & Development was $83762.0 for Q1 2026 at China Pharma Holdings, down from $190041.0 in the prior quarter.
- Across five years, Research & Development topped out at $190041.0 in Q4 2025 and bottomed at $547.0 in Q4 2024.
- A 5-year average of $63208.4 and a median of $40321.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 99.63% — and 2025, when it soared 34642.41%.
- China Pharma Holdings' Research & Development stood at $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then tumbled by 99.63% to $547.0 in 2024, then surged by 34642.41% to $190041.0 in 2025, then slumped by 55.92% to $83762.0 in 2026.
- Business Quant data shows CPHI's Research & Development at $83762.0 in Q1 2026, $190041.0 in Q4 2025, and $40321.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 83,762.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83,762.00 |
| Dec 31, 2025 | 190,041.00 |
| Sep 30, 2025 | 40,321.00 |
| Jun 30, 2025 | 20,952.00 |
| Mar 31, 2025 | 29,587.00 |
| Dec 31, 2024 | 547.00 |
| Sep 30, 2024 | 87,610.00 |
| Jun 30, 2024 | 164,334.00 |
| Mar 31, 2024 | 31,451.00 |
| Dec 31, 2023 | 147,552.00 |
| Sep 30, 2023 | 45,773.00 |
| Jun 30, 2023 | 23,747.00 |
| Mar 31, 2023 | 23,008.00 |
| Dec 31, 2022 | 27,999.00 |
| Sep 30, 2022 | 88,747.00 |
| Jun 30, 2022 | 15,063.00 |
| Mar 31, 2022 | 54,049.00 |
| Dec 31, 2021 | 54,048.00 |
| Sep 30, 2021 | 21,374.00 |
| Jun 30, 2021 | 53,456.00 |